Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jessica J Lin

Showing results (1-10 of 92) with videos related to

Pageof 10
Sort By:
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 19, 2017
Recent Advances in Targeting ROS1 in Lung CancerJessica J Lin, Alice T Shaw
British Journal of Cancer|March 24, 2021
An early look at selective RET inhibitor resistance: new challenges and opportunitiesJessica J Lin, Justin F Gainor
Trends in Cancer|November 8, 2016
Resisting Resistance: Targeted Therapies in Lung CancerJessica J Lin, Alice T Shaw
Trends in Cancer|January 31, 2025
Evolution of first versus next-line targeted therapies for metastatic non-small cell lung cancerSarah Waliany, Jessica J Lin, Justin F Gainor
The Oncologist|August 23, 2024
Advances and future directions in ROS1 fusion-positive lung cancerMary C Boulanger, Jaime L Schneider, Jessica J Lin
Nature Reviews. Clinical Oncology|May 9, 2022
Third-generation EGFR and ALK inhibitors: mechanisms of resistance and managementAlissa J Cooper, Lecia V Sequist, Jessica J Lin
Nature Cancer|February 16, 2023
ALK-positive lung cancer: a moving targetJaime L Schneider, Jessica J Lin, Alice T Shaw
Cancer Discovery|January 27, 2017
Targeting ALK: Precision Medicine Takes on Drug ResistanceJessica J Lin, Gregory J Riely, Alice T Shaw
Cancer Discovery|June 3, 2024
Unlocking the Next Frontier in Precision Oncology: Addressing Drug-Tolerant Residual DiseaseJessica J Lin, Justin F Gainor, Vincent K Lam, et al.
Cancer Cell|January 11, 2022
LTK fusions: A new target emerges in non-small cell lung cancerAlissa J Cooper, Lecia V Sequist, Ted W Johnson, et al.
Pageof 10

Showing results (1-10 of 92) with videos related to

Sort By:
Pageof 10
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 19, 2017
Recent Advances in Targeting ROS1 in Lung CancerJessica J Lin, Alice T Shaw
British Journal of Cancer|March 24, 2021
An early look at selective RET inhibitor resistance: new challenges and opportunitiesJessica J Lin, Justin F Gainor
Trends in Cancer|November 8, 2016
Resisting Resistance: Targeted Therapies in Lung CancerJessica J Lin, Alice T Shaw
Trends in Cancer|January 31, 2025
Evolution of first versus next-line targeted therapies for metastatic non-small cell lung cancerSarah Waliany, Jessica J Lin, Justin F Gainor
The Oncologist|August 23, 2024
Advances and future directions in ROS1 fusion-positive lung cancerMary C Boulanger, Jaime L Schneider, Jessica J Lin
Nature Reviews. Clinical Oncology|May 9, 2022
Third-generation EGFR and ALK inhibitors: mechanisms of resistance and managementAlissa J Cooper, Lecia V Sequist, Jessica J Lin
Nature Cancer|February 16, 2023
ALK-positive lung cancer: a moving targetJaime L Schneider, Jessica J Lin, Alice T Shaw
Cancer Discovery|January 27, 2017
Targeting ALK: Precision Medicine Takes on Drug ResistanceJessica J Lin, Gregory J Riely, Alice T Shaw
Cancer Discovery|June 3, 2024
Unlocking the Next Frontier in Precision Oncology: Addressing Drug-Tolerant Residual DiseaseJessica J Lin, Justin F Gainor, Vincent K Lam, et al.
Cancer Cell|January 11, 2022
LTK fusions: A new target emerges in non-small cell lung cancerAlissa J Cooper, Lecia V Sequist, Ted W Johnson, et al.
Pageof 10